Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 1;56(11):1847-1856.
doi: 10.1093/rheumatology/kew464.

Dosing down with biologic therapies: a systematic review and clinicians' perspective

Christopher J Edwards  1 , Bruno Fautrel  2 , Hendrik Schulze-Koops  3 , Tom W J Huizinga  4 , Klaus Kruger  5
Affiliations

Dosing down with biologic therapies: a systematic review and clinicians' perspective

Christopher J Edwards et al. Rheumatology (Oxford). .

Erratum in

Abstract

The effectiveness of biologic therapies now means that remission or low disease activity are realistic targets for treatment. However, after achieving remission/low disease activity, the next steps remain unclear. The aim of this publication was to conduct a broad systematic literature review to evaluate dosing down of biologics. After screening papers and abstracts for relevance and application of inclusion/exclusion criteria, a structured extraction process was used to collect information on the included studies. Fifty-two papers were included in the analysis across rheumatic disease. In patients who discontinue therapy, remission is not typically sustained, with reported rates of relapse and flare across early RA (48-54%), established RA (2-84%), axial spondyloarthritis (11-53%) and PsA (44.9%). In many cases, an acceptable disease activity can be regained upon retreatment. More research is needed to understand the long-term impacts of these strategies on efficacy, safety and cost.

Keywords: axial spondyloarthritis; biologic therapy; dose spacing; dose tapering; dosing down; psoriatic arthritis; rheumatoid arthritis; systematic review; treatment withdrawal.

PubMed Disclaimer

Figures

F<sc>ig</sc>. 1
Fig. 1
Selection of studies flowchart
See this image and copyright information in PMC

References

    1. Smolen JS, Landewé R, Breedveld FC. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492–509. - PMC - PubMed
    1. Gossec L, Smolen JS, Gaujoux-Viala C. et al. European League Against Rheumatism. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4–12. - PubMed
    1. Braun J, van den Berg R, Baraliakos X. et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896–904. - PMC - PubMed
    1. Smolen JS, Aletaha D, Bijlsma JW, T2T Expert Committee et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631–7. - PMC - PubMed
    1. Smolen JS, Braun J, Dougados M. et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73:6–16. - PMC - PubMed

Publication types

MeSH terms